A 24 week double-blind, randomised, placebo-controlled, parallel-group dose-ranging study to investigate the effects of rosiglitazone (extended release tablets) on cognition in subjects with mild to moderate Alzheimer's disease
Alzheimer's Disease
Phase 2
A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
September 2013